Table 2. Distribution of actual and predicted progression-free survival of patients with lung squamous cell carcinoma.
| Predicted results | |||||||
|---|---|---|---|---|---|---|---|
| Training phase a | Validation phase | ||||||
| PFS > 2 years, n (%) | PFS <= 2 years, n (%) | Total, n | PFS > 2 years, n (%) | PFS <= 2 years, n (%) | Total, n | ||
| Actual results | PFS > 2 years, n (%) | 49 (94.2) b | 3 (5.8) | 52 | 18 (100) d | 0 (0) | 18 |
| PFS <= 2 years, n (%) | 5 (14.3) | 30 (85.7) c | 35 | 4 (15.4) | 22 (84.6) e | 26 | |
| Total, n | 54 | 33 | 87 | 22 | 22 | 44 | |
a
Leave-one-out cross-validated grouped cases.
b, c
The sensitivity b and specificity c for identifying PFS > 2 years were 94.2% and 85.7% for the training sets of leave-one-out cross-validated grouped cases, respectively.
d, e
The sensitivity d and specificity e for identifying PFS > 2 years were 100% and 84.6% for the validation cases, respectively.